Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal November 5, 2020 Akebia Therapeutics Inc AKBA Morningstar Rating Rating as of Nov 23, 2020. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a ⦠News provided by. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates finance.yahoo.com - November 7 at 8:14 AM: Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript seekingalpha.com - November 6 at 2:26 PM: Akebia Therapeutics Inc (AKBA) Q3 2020 Earnings Call Transcript The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. In Q2, Akebia Therapeutics (NASDAQ: AKBA) posted sales of $90.14 million. CAMBRIDGE, Mass., June 18, 2020 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced David A. Spellman is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, effective June 29, 2020. Share this article. Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic … Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. The two INNO 2 VATE studies evaluated the efficacy and safety ⦠Press Releases. Akebia Therapeutics News: This is the News-site for the company Akebia Therapeutics on Markets Insider The Cambridge, Massachusetts-based company said it had a loss of 42 cents per share. From 2000 to 2006, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs at Genzyme Corporation, where he worked from 2001 to 2006. Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights October 23, 2020 Akebia Presents Results from its PRO₂TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 … The company’s stock price has collected 0.85% of gains in the last five trading sessions. News provided by. All news about AKEBIA THERAPEUTICS, INC. 09:38a: AKEBIA THERAPEUTICS: Ranked 10th Fastest-Growing Company in North America on De.. PR. Press Release reported 16 hours ago that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights Cambridge, MA 02142, +1 617.871.2098 phone +1 617.871.2099 fax. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500â¢, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America, now in its 26th year. PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ⦠Why Akebia Therapeutics Stock Is Crashing Today The company's lead pipeline candidate fell short in a late-stage clinical study. Recently in News on November 24, 2020, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. Earnings were up 193.99%, but Akebia Therapeutics still reported an overall loss of $173.82 million. 07:01a: AKEBIA THERAPEUTICS: Announces Top-Line Results from its PRO2TECT Global Phase .. PR. Several other experts on Wall Street have posted such reports regarding the AKBA shares. 245 First Street, Suite 1400 ROCE Insights For Akebia Therapeutics. The stock had previously closed at $2.88. There are some variant perceptions on Akebia Therapeutics, with the most bullish analyst valuing it at US$10.00 and the most bearish at US$3.00 per share. 11/19: AKEBIA THERAPEUTICS: Ranked 10th Fastest-Growing Company in North America on De.. AQ. Find the latest news headlines from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. A number of […] CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to … Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500⢠November 16, 2020. The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to … Akebia Therapeutics: The Drop From The Missed Safety Endpoint Offers A Good Reentry Point . CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive top-line results from INNO 2 VATE, the first of its two global Phase 3 cardiovascular outcomes programs. Below are the latest news stories about Akebia Therapeutics Inc that investors may wish to consider to help them evaluate AKBA as an investment opportunity. 2 min read (Reuters) - Akebia Therapeutics Inc said on Thursday its experimental drug failed to meet the main safety …